

***Explanation of Conflict of Interest Disclosure Parts:***

**Part One:** All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present)

**Part Two:** Income Sources & Equity of \$10,000 or greater

**Part Three:** Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present):

**Part Four:** Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present)

**Part Five:** My primary employer is a pharmaceutical/biotech/medical device company.

**2012 Program Committee Disclosures**

**Anissa Abi-Dargham:** *Part 1:* Pfizer; Otsuka; Takeda; Sunovion; Shire; Roche; Pierre Favre; *Part 2:* Pierre Favre

**William Carlezon:** *Part 1:* Referring to 2010-2011: Scientific Advisory Board, Myneurolab.com; Consultant, Concert Pharmaceuticals; Consultant, Lantheus Medical Imaging; Consultant, Transcept Pharmaceuticals, (Spouse) Senior Scientist, EMD Serono; *Part 2:* (Spouse) Senior Scientist, EMD Serono, *Part 3:* (Spouse) Senior Scientist, EMD Serono

**Cameron Carter:** *Part1:* GlaxoSmithKline research; *Part 4:* GlaxoSmithKline

**Karl Deisseroth:** *Part 1:* Co-founder of Circuit Therapeutics

**Walter Kaye:** *Part 1:* A2 grant; *Part 2:* NCSP Faculty support and NIH grant, Price Foundation grant support; *Part 4:* A2

**Richard Keefe:** *Part 1:* Abbott, Astellas, Asubio, BiolineRx, BrainCells, Bristol-Myers Squibb, Cypress Bioscience, Eli Lilly, EnVivo, Lundbeck, Merck, NeuroCog Trials, Inc., Pfizer, Roche, Sanofi-Aventis, Shire, Solvay, Sunovion, Takeda, and Wyeth; *Part 2:* Abbott, BiolineRx, Cypress Bioscience, Eli Lilly, EnVivo, Lundbeck, Merck, NeuroCog Trials, Inc., Pfizer, Roche, Shire, Sanofi-Aventis, Sunovion; *Part 3:* NeuroCog Trials, Inc.; *Part 4:* GSK, Novartis, Psychogenics

**Henry Kranzler:** *Part 1:* Alkermes, Lundbeck, GlaxoSmithKline, Roche, Gilead, ACTIVE group received support from Eli Lilly, Janssen, Schering Plough, Alkermes, Lundbeck, GlaxoSmithKline, Abbott and Johnson and Johnson; *Part 2:* Alkermes, Lundbeck

**Kaplana Merchant:** *Part 1:* Eli Lilly and Company; *Part 2:* Eli Lilly and Company; *Part 3:* Eli Lilly and Company; *Part 5:* Eli Lilly and Company

**Andreas Meyer-Lindenberg:** *Part 1:* Astra Zeneca, Servier, F. Hoffmann-La Roche Ltd., Pfizer Pharma GmbH, Janssen-Cilag EMEA, F. Hoffmann-La Roche Ltd., Lilly Deutschland GmbH, Gerson Lehrmann Group (GLG), Pricewise, Elsevier, Alexza Pharmaceuticals Inc., Pfizer Pharma GmbH, Astra Zeneca, Outcome Sciences Inc., Desitin Arzneimittel GmbH, Defined Health, Bristol-Myers Squibb GmbH & Co.KGaA

**Lisa Monteggia:** *Part 1:* Speaker's Bureau: Roche, Lundbeck

**John Rubenstein:** *Part 1:* Neurona Scientific Board

**Akira Sawa:** *Part 1:* Research Funding: Astellas, Takeda, Tanabe-Mitsubishi, Dainippon-Sumitomo. Consultant: Pfizer, Asubio, Sucampo, Eli Lilly, Taisho, Amgen. Collaboration: Pfizer, Afraxis, Sanofi-Aventis, Astrazeneca, Johnson and Johnson

**Darryle Schoepp:** *Part 1:* Employee of Merck and Co., Inc., *Part 2:* Merck and Co., Inc., *Part 3:* Employee of Merck and Co., Inc., *Part 4:* Employee of Merck and Co., Inc.; *Part 5:* Employee of Merck and Co.

**David Self:** *Part 1:* Associate Editor, Neuroscience Letters, Elsevier, Investor, Noorik Biopharmaceuticals Ltd., Riehen, Switzerland; *Part 2:* Investor, Noorik Biopharmaceuticals Ltd., Riehen, Switzerland

**David Sibley:** *Part 2:* National Institutes of Health (primary employer), American College of Neuropsychopharmacology (editor), American Society for Pharmacology and Experimental Therapeutics (editor), Corporate Resources, LLC (spouse's company)

**Pamela Sklar:** *Part 1:* Pfizer

**Trisha Suppes:** *Part 1:* AstraZeneca, Pfizer Inc., National Institute of Mental Health, Sunovion Pharmaceuticals, Jones and Bartlett (formerly Compact Clinicals); *Part 4:* AstraZeneca, Pfizer Inc., Sunovion Pharmaceuticals

**Matthew State:** *Part 1:* Scientific Advisory Board for Pfizer, Consultant for SynapDx, *Part 2:* Pfizer, Scientific Advisory Board

**Audrey Tyrka:** *Part 1:* Medtronic, Neuronetic, NeoSync, Lundbeck; *Part 4:* Medtronic, Neuronetic, NeoSync

**Dean Wong:** *Part 2:* employed by the Johns Hopkins University, School of Medicine, (spouse) employed by NIA/NIH.; *Part 4:* NIH, Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis

**Carlos Zarate:** *Part 1:* listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Dr. Zarate has assigned his rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government

***Program Committee Members with No Disclosures:***

Ted Abel  
Victoria Arango  
Aysenil Belger  
Karen Berman  
Randy Blakely  
Hilary Blumberg  
Kristin Cadenhead  
Michael Davidson  
Jay Gingrich  
Paul Kenny  
Thomas Lehner  
Arnold Mandell  
Karoly Mirnics  
Bita Moghaddam  
Kerry Ressler  
Etienne Sibille  
Arielle Stanford  
Daniel Weinberger  
Rachel Yehuda

## ACNP 2012 Presenter Disclosures

**Bryon Adinoff:** *Part 1:* Auxilium Pharmaceuticals, Shook, Hardy & Bacon LLP (medical malpractice consultant, tobacco companies), *Part 2:* Department of Veterans Affairs, UT Southwestern Medical Center

**Caleb Adler:** *Part 1:* I have participated in multi-site trials including AstraZeneca, Eli Lilly, Pfizer, Otsuka, Forest, Sunovion, Novartis, Glaxo Smith-Kline, and Amylin. I have received research support from AstraZeneca. I have been a speaker and consultant for Merck., *Part 2:* Merck, *Part 3:* Merck, *Part 4:* AstraZeneca

**Evdokia Anagnostou:** *Part 1:* Consultation fee from SeaSide Therapeutics Consulted without fees to Novartis, *Part 4:* Forest has provided free drug and placebo for a clinical trial

**Celso Arango:** *Part 1:* Dr. Arango. has been a consultant to or has received honoraria or grants from Astra Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Merck, Otsuka, Pfizer, Roche, Servier and Schering Plough., *Part 4:* Dr. Arango has received grants from Roche and Lundbeck.

**Steven Arnold:** *Part 1:* Bristol Myers Squibb [advisor board], *Part 4:* Dr. Arnold has received research support from the NIH (R01AG039478, R01AG15819, P30AG10161, P30AG10124, P50MH64045, R01MH075916, R01 DA023210, R01 DA023210, R01 DA025201), the Marian S. Ware Charitable Giving Fund, the Penn Pfizer Alliance, Johnson & Johnson, Neuronetrix, Eli Lilly, American College of Radiology Imaging Network.

**David Baker:** *Part 1:* Promentis Pharmaceuticals (2010-present), *Part 2:* Promentis Pharmaceuticals (2010-present), *Part 3:* Promentis Pharmaceuticals (2010-present), *Part 4:* Promentis Pharmaceuticals (2010-present)

**Deanna Barch:** *Part 1:* I have research grants from Novartis and Allon, and I served as a consultant for Pfizer., *Part 4:* Allon and Novartis

**Ruth Benca:** *Part 1:* Consultant to Merck and Sanofi-aventis.

**John Blangero:** *Part 4:* Eli Lilly and Co.

**Floyd Bloom:** *Part 1:* I am a Founder and Director of Alkermes,plc. and as such I am also a shareholder in this publicly traded company., *Part 2:* I am retired. My income sources are from general investments and 401k plans, and from two chairitable remainder trusts., *Part 3:* I am a

consultant to Elan Pharma, Inc, as well as a Director of Alkermes,plc. Nither relationship nor any of my other smaller consulting agreements amounts to 5% of my personal income.,

**Johannes Bohacek:** *Part 4:* Roche (post-doctoral fellowship)

**Michael Bogenschutz:** *Part 2:* Salary from the University of New Mexico

**Christopher Bowie:** *Part 1:* I have been a consultant and advisory board member for Abbott Pharmaceuticals from 2010 to present.

**Nicholas Brandon:** *Part 1:* I am a full time employee of Pfizer, *Part 2:* I am a full time employee of Pfizer, *Part 3:* I am a full time employee of Pfizer

**Edward Bullmore:** *Part 1:* GlaxoSmithKline Employee 0.5 FTE, *Part 2:* Income and equity from GlaxoSmithKline, *Part 3:* GlaxoSmithKline Employee 0.5 FTE, *Part 5:* I work half-time for GlaxoSmithKline and half-time for the University of Cambridge

**Blynn Bunney:** *Part 1:* NeoSync

**Ronald Burch:** *Part 1:* I am an employee of Naurex, Inc, the Sponsor of the clinical study reported herein., *Part 2:* Naurex, Inc, *Part 3:* Naurex, Inc

**Marc Caron:** *Part 1:* Lundbeck, Omeros, Roche, Forest Laboratories., *Part 2:* Omeros, *Part 4:* Lundbeck, Roche, Forest Laboratories

**William Carpenter:** *Part 1:* I have served as a consultant to Lundbeck, Eli Lilly and Company, Bristol-Meyers Squibb, Shire Pharmaceuticals, and AstraZeneca

**Kiki Chang:** *Part 1:* Dr. Chang is a consultant for GSK, Merck, BMS, and Lilly. He receives research funding from GSK and Merck., *Part 4:* GSK, Merck

**Charles Chavkin:** *Part 1:* Consulting for Trevena 2010-2011, *Part 4:* Contract with Trevena 2010-2011

**Guang Chen:** *Part 1:* Janssen Pharmaceutical Companies of Johnson and Johnson, *Part 2:* Janssen Pharmaceutical Companies of Johnson and Johnson, *Part 3:* Janssen Pharmaceutical Companies of Johnson and Johnson, *Part 4:* Janssen Pharmaceutical Companies of Johnson and Johnson

**David Collier:** *Part 1:* David Collier will become an employee of Eli Lilly on April 23rd 2012.

**Wilson Compton:** *Part 1:* Pfizer, General Electric, *Part 2:* None. No income and equity is less than \$10,000 in total for both entities listed above (General Electric and Pfizer)., *Part 3:* None.

**P. Jeffrey Conn:** *Part 2:* Consulting fee and licensing income through Vanderbilt University from Karuna Pharmaceuticals Licencing income through Vanderbilt University from Johnson and Johnson, Seaside Therapeutics Own equity that does not generate income in Seaside Therapeutics, Karuna Pharmaceuticals, *Part 4:* Johnson and Johnson, Seaside Therapeutics

**Edwin Cook:** *Part 1:* Consultation - Seaside Therapeutics - 2010, *Part 4:* Seaside Therapeutics - support for site in a multi-site clinical trial

**Christoph Correll:** *Part 1:* Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; AstraZeneca, Biotis, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Desitin, Eli Lilly, GSK, IntraCellular Therapies, Lundbeck, Medavante, Medicure, Medscape, Merck, National Institute of Mental Health, Novartis, Ortho-McNeill/Janssen/J&J, Otsuka, Pfizer, ProPhase, Schering-Plough, Sepracor/Sunovion, Supernus, Takeda, Teva and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Janssen/J&J, National Institute of Mental Health (NIMH), National Alliance for Research in Schizophrenia and Depression (NARSAD),and Otsuka. , *Part 2:* AstraZeneca, Bristol-Myers Squibb, GSK, Otsuka, Pfizer, ProPhase., *Part 3:* AstraZeneca, Bristol-Myers Squibb, GSK, Otsuka, Pfizer, ProPhase., *Part 4:* BMS, Janssen/J&J ,and Otsuka.

**David Cotter:** *Part 1:* honorarium research presentation x1 Lilly

**Joseph Coyle:** *Part 2:* Abbott Pharmaceutical, *Part 4:* BristolMeyerSquibb

**John Csernansky:** *Part 1:* Membership on a Data Monitoring Committee for Eli Lilly and Co.

**Bruce Cuthbert:** *Part 2:* NIMH Salary

**Kenneth Davis:** *Part 1:* My wife, Bonnie Morrison Davis, MD, is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income frm this license., *Part 2:* My wife, Bonnie Morrison Davis, MD, is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income frm this license., *Part 3:* My wife, Bonnie Morrison Davis, MD, is a patent holder on the use patent for galantamine for Alzheimer's disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson. She receives royalty income from this license.

**Geraldine Dawson:** *Part 1:* Professional Advisory Board for Integragen, Inc. from which I receive compensation for scientific advice.

**Steven DeKosky:** *Part 1:* Helicon Therapeutics Genzyme Merck , *Part 2:* none other than primary employment at the University of Virginia, *Part 4:* Elan Pharmaceuticals Novartis Janssen Forest

**Melissa DelBello:** *Part 1:* Eli Lilly, Amylin, AstraZeneca, Pfizer, Bristol Myers Squibb, Janssen, Johnson and Johnson, Somerset, Shire, Novartis, *Part 2:* Bristol Myers Squibb, Merck, *Part 3:* Bristol Myers Squibb, *Part 4:* Eli Lilly, Amylin, AstraZeneca, Pfizer, Bristol Myers Squibb, Janssen, Johnson and Johnson, Somerset.

**Michael Detke:** *Part 1:* MedAvante, Sonkei, Rhine, Columbia, Roche, NIH Pharnanet/i3/Inventiv (partner), *Part 2:* MedAvante, *Part 3:* MedAvante

**Wayne Drevets:** *Part 1:* Johnson & Johnson, consultant, Esai, Inc., consultant, Myriad/ Rules Based Medicine, consultant, *Part 2:* Johnson & Johnson

**Ronald Duman:** *Part 1:* Lundbeck, Lilly, Taisho, Forest, J&J, Bristol Myers Squibb, Pfizer, *Part 4:* Lundbeck, Lilly, Forest, J&J

**Elliot Ehrich:** *Part 1:* Alkermes plc, Full time employee, *Part 2:* Alkermes plc, Full time employee, *Part 3:* Alkermes plc, Full time employee

**Wissam El-Hage:** *Part 1:* WEH acted as a speaker or consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Janssen, Lundbeck, and Servier France.

**Mary-Anne Enoch:** *Part 2:* Government salary, two homes, one car

**Cagla Eroglu:** *Part 4:* Mazorx Inc provided a grant that supported our efforts to find activity blocking antibodies against TSPs.

**Amit Etkin:** *Part 4:* Grant from Brain Resource, Inc. for taking part in the International Study to Predict Optimized Treatment in Depression (iSPOT-D)

**A. Eden Evins:** *Part 1:* Pfizer, GSK, Envivo Pharmaceuticals, *Part 4:* Pfizer, GSK, Envivo Pharmaceuticals

**Peter Falkai:** *Part 1:* Until the end of 2010 I have been giving paid lectures and was on the advisory boards of the following pharmaceutical companies: Lilly, Servier, AstraZeneca,

Janssen-Cilag, Pfizer and Lundbeck., *Part 2*: 20.000 US dollars., *Part 3*: No financial involvement of this amount., *Part 4*: I am currently having a grant from Servier.

**Ellen Frank:** *Part 1*: Servier International (Consultant) Vanda Pharmaceuticals (Consultant) Guilford Press and American Psychological Association Publishing (Royalties), *Part 2*: Servier International (Consultant) Spouse: Consultant to the American Psychiatric Association

**Alan Frazer:** *Part 1*: Lundbeck Takeda Lilly Cyberonics, *Part 4*: Lundbeck

**Marlene Freeman:** *Part 1*: Investigator-Initiated Trials (grants to MGH): Forest, Lilly, GlaxoSmithKline; 1 day advisory board: Bristol Myers Squibb, *Part 2*: Journal of Clinical Psychiatry, *Part 4*: Investigator-Initiated Trials (grants to MGH): Forest, Lilly, GlaxoSmithKline; 1 day advisory board: Bristol Myers Squibb

**Jeffrey Friedman:** *Part 1*: Envoy Therapeutics, Bay City Capital, Anglian Pharmaceutical, *Part 2*: Envoy Therapeutics, Bay City Capital, Anglian Pharmaceutical

**Adam Gazzaley:** *Part 1*: Akili Interactive Labs, Patent filed: "Enhancing Cognition in the Presence of Distraction and/or Interruption," *Part 2*: Akili Interactive Labs

**Daniel Geschwind:** *Part 1*: Synapdx -- scientific advisory board/consultant Roche -- ad hoc advisory board., *Part 2*: Synapdx 2011-2012

**Donald Goff:** *Part 1*: In the past 2 years Dr. Goff has received honoraria for consulting or speaking from Hoffman-La Roche, Eli Lilly, Takeda, Dainippon Sumitomo, Endo Pharmaceuticals, Janssen, Cypress Bioscience, Bristol Myer Squibb, Abbott Laboratories and served on a DMC for Otsuka., *Part 4*: Dr. Goff received research funding from Pfizer, GlaxoSmithKline, Janssen, Novartis and PamLab

**David Goldman:** *Part 2*: NIH - salary Elsevier - book contract American Century - Mutual Fund Thrift Savings Plan - IRA Home Car

**Anthony Grace:** *Part 1*: Johnson & Johnson, Lundbeck, Pfizer, GSK, Puretech Ventures, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, *Part 2*: Johnson & Johnson, *Part 3*: Johnson & Johnson, *Part 4*: Lundbeck, GSK, Lilly

**Guy Griebel:** *Part 1*: Employee of Sanofi.

**Roland Griffiths:** *Part 1*: Heffter Research Institute - Member of Board of Directors - 2 grants for clinical trials with psilocybin Transcept Pharmaceutical - consulting Alexza Pharmaceuticals



- grant for clinical trial Bristol-Myers Squibb - consulting Merck and Co - consulting Vanda Pharmaceuticals - consulting, *Part 4*: Alexza Pharmaceutical --A grant was provided to Johns Hopkins to conduct an abuse liability evaluation with a novel drug delivery system Heffter Research Institute -- Two grants to conduct clinical trials with psilocybin

**Dimitri Grigoriadis:** *Part 1*: I am a full time employee of Neurocrine Biosciences Inc., *Part 2*: Salary and Equity associated with full time employment at Neurocrine Biosciences Inc., *Part 3*: I am a full time employee of Neurocrine Biosciences Inc.

**Ruben Gur:** *Part 2*: Defender's association and Federal and State courts (detailed in my disclosure to the University)., *Part 4*: Investigator-initiated grants from Pfizer and AstraZeneca

**Jan-Ake Gustafsson:** *Part 1*: Consultant for KaroBio AB., *Part 2*: Consultancy fee from KaroBio AB., *Part 3*: No., *Part 4*: No.

**Suzanne Haber:** *Part 1*: Pfizer

**Chang-Gyu Hahn:** *Part 4*: Pfizer Pharmaceuticals

**Paul Harrison:** *Part 1*: Honoraria for scientific talks: AstraZeneca, Otsuka, Takeda Advisory board: Merck, *Part 2*: University of Oxford , *Part 4*: Unrestricted educational grant from Takeda (Cambridge, UK) to the Department of Psychiatry, University of Oxford

**Markus Heilig:** *Part 2*: none other than primary employment by the US Federal Government

**W. Joseph Herring:** *Part 1*: Presenter is an employee of Merck., *Part 2*: Merck, *Part 3*: Merck

**Ian Hickie:** *Part 1*: Paid Educational Seminars/Resources Servier Astra Zeneca Pfizer Eli-Lilly Travel Support from Pharmaceutical or Business Companies Servier Astra Zeneca Price Waterhouse Cooper Research Support from Pharmaceutical Companies: Servier Pfizer , *Part 2*: Professor of Psychiatry, University of Sydney Executive Director, Brain & Mind Research Institute, University of Sydney Clinical Consultant in Psychiatry, Sydney Local Health District (NSW Government Services) Bupa Australia (Private Health Insurance) - Member of the Medical Advisory Panel Headspace: the National Youth Mental Health Foundation- Director on behalf of the University of Sydney, which is a member of the Company.( ENDED JAN 2012, *Part 4*: Hickie I. (2011-2012) Project: Does circadian disturbance predict response to sleep-wake interventions in early-onset depression. Servier, \$100,000.

**Florian Holsboer:** *Part 1*: Cofounder of HMNC GmbH (Biotech Company) Cofounder and shareholder of Affectis AG (Biotech Company)

**Steven Hyman:** *Part 1:* Novartis Science Board, *Part 2:* Novartis Fidelity Biosciences (Venture) Access BridgeGap (Venture)

**Iliyian Ivanov:** *Part 1:* Member of Data Safety Monitoring Board for Lundbeck., *Part 4:* Co-investigator on a neuroimaging grant from Shire awarded to Dr Jeffrey Newcorn at Mount Sinai School of Medicine.

**Daniel Javitt:** *Part 1:* Solvay, Sepracor, AstraZeneca, Pfizer, Cypress, Merck, Sunovion, Lilly, BMS, Takeda, Glytech, AASI, Promentis, *Part 2:* Pfizer, Glytech, *Part 3:* Glytech, *Part 4:* Pfizer, Roche,

**Jarcho Johanna:** *Part 2:* National Institute of Health postdoctoral fellowship stipend

**Rene Kahn:** *Part 1:* AstraZeneca, BMS, Lilly, Otsuka, Roche, Sunovion

**Ned Kalin:** *Part 1:* Neuronetics CeNeRx BioPharma Corcept Therapeutics CME Outfitters Elsevier, *Part 2:* Elsevier, *Part 3:* Not applicable, *Part 4:* APIRE/Janssen Resident Psychiatric Mentor Grant National Institute of Mental Health The Stanley Medical Research Institute

**Peter Kalivas:** *Part 2:* Medical University of South Carolina Medical University Associates

**Shitij Kapur:** *Part 1:* Has served as a one-off consultant and/or speaker for AstraZeneca, Bioline, Bristol Myers Squibb, Eli Lilly, Envivo, Janssen - Johnson and Johnson, NeuroSearch, Otsuka, Pfizer, Sanofi-Aventis, Schering-Plough, Servier, Solvay Wyeth and serves on the Scientific Advisory Boards for Lundbeck and Roche., *Part 4:* GSK, Lundbeck.

**Richard Keefe:** *Part 1:* Abbott, Amgen, Astellas, Asubio, Boehringer-Ingelheim, BiolineRx, Bristol-Myers Squibb, Eli Lilly, EnVivo, Helicon, Lundbeck, Merck, Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept, *Part 2:* Abbott, Amgen, BiolineRx, Eli Lilly, EnVivo, Lundbeck, Mitsubishi, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept, *Part 3:* NeuroCog Trials, Inc., *Part 4:* GSK, Novartis, PsychoGenics, Sunovion

**Matcheri Keshavan:** *Part 1:* I have received two grants, one from Sunovion and another from GSK, in the last two years., *Part 4:* I have received two grants, one from Sunovion and another from GSK, in the last two years.

**Thomas Kilduff:** *Part 1:* Since I am not a member of ACNP, I have no idea what "companies doing business with or proposing to do business with ACNP over past 2 years.", *Part 4:* CHDI EMD Serono Research Institute F. Hoffman-La Roche, Ltd. Sunovion

**Michael Kilgard:** *Part 1:* I am a consultant for and have a financial interest in MicroTransponder, Inc., *Part 2:* I am a consultant for MicroTransponder, Inc., *Part 3:* I am a consultant for MicroTransponder, Inc., *Part 4:* I have a sub-contract from MicroTransponder, Inc. to conduct research that is supported in part by the NIH.

**Lori Knackstedt:** *Part 2:* MUSC

**Scott Kollins:** *Part 1:* Research Support: Rhodes Pharmaceuticals, Shire Pharmaceuticals, Otsuka Pharmaceuticals, Addrenex/Shionogi Pharmaceuticals Consultant/Advisory Board: Shire Pharmaceuticals, Otsuka Pharmaceuticals, Addrenex/Shionogi Pharmaceuticals, WebMD/Medscape, *Part 2:* Shire Pharmaceuticals, Otsuka Pharmaceuticals, *Part 4:* Shire Pharmaceuticals

**George Koob:** *Part 1:* Addes, Alkermes, Arkeo, Embera, Psychogenics

**Andrew Krystal:** *Part 1:* Abbott, Astellas, AstraZeneca, BMS, Cephalon, Eisai, Eli Lilly, GlaxoSmithKline, Jazz, Johnson and Johnson, MECTA Corp, Merck, Neurocrine, Novartis, Ortho-McNeil-Janssen, Respiroics, Roche, Sanofi-Aventis, Somnus, Sunovion/Sepracor, Somaxon, Takeda, Transcept, Kingsdown Inc., *Part 4:* NIH, Cephalon, Pfizer, Sunovion/Sepracor, Takeda, Transcept, Phillips-Respiroics, Astellas, Abbott, Neosynch, Brainsway.

**David Kupfer :** *Part 2:* University of Pittsburgh American Psychiatric Association

**Steven Kymes:** *Part 1:* I am a consultant and receive (or have received) research funding for Pfizer, Bayer and Genentech., *Part 2:* Consulting fees from Bayer in excess of \$10,000 in 2011 and 2012, *Part 4:* As noted above, Pfizer and Genenech in 2010 and 2011.

**Paul Lombroso:** *Part 1:* President, STEP Solutions, New Haven, CT, *Part 2:* \$0

**Dan Lubman:** *Part 1:* Honorarium for lectures (AstraZeneca, Janssen)

**Angus MacDonald:** *Part 2:* University of Minnesota

**Robert Malenka:** *Part 1:* Circuit Therapeutics, Inc. SAB member

**Craig Mallinckrodt:** *Part 1:* Employee of Eli Lilly and Co, *Part 2:* Employee of Eli Lilly and CO, *Part 3:* Employee of Eli Lilly and Co

**Husseini K. Manji:** *Part 1:* Husseini Manji is a full time salaried employee of Johnson & Johnson, *Part 2:* Husseini Manji is a full time salaried employee of Johnson & Johnson, *Part 3:* Husseini Manji is a full time salaried employee of Johnson & Johnson, *Part 4:* Husseini Manji is a full time salaried employee of Johnson & Johnson

**Stephen Marder:** *Part 1:* Consultant: Abbott, Amgen, Targacept, Lundbeck, Pfizer, Roche, Bristol Meyers Squibb, Otsuka., *Part 4:* Research Support: Novartis, GSK, Sunovion, Psychogenics

**Barbara Mason:** *Part 1:* SAB: Addex Pharmaceuticals, Lohocla Research Corporation; Consultant: Johnson & Johnson Pharmaceutical Research & Development, LLC, Lilly USA, LLC; Speaker: Merck KGaA

**Colleen McClung:** *Part 1:* I have received honoraria from Johnson & Johnson, Servier, and Pfizer, *Part 4:* We received research funding from GlaxoSmithKline and Pfizer

**James Meador-Woodruff:** *Part 2:* Primary employer University of Alabama School of Medicine and University of Alabama Health Services Foundation; ACNP provides an honorarium for service as Editor in Chief of Neuropsychopharmacology, *Part 4:* American Foundation for Suicide Prevention and Ortho-McNeil. Served as PI on an Investigator Initiated project (jointly funded by both) for three month transition between original and current PIs.

**Lin Mei:** *Part 1:* SAB member, Mind-NRG

**Kalpna Merchant:** *Part 1:* I am an employee of Eli Lilly and company, a major pharmaceutical company., *Part 2:* As an employee of Eli Lilly and company, I receive income and equity from the company., *Part 3:* I am an employee of Eli Lilly and company, a major pharmaceutical company.

**Jeffrey Meyer:** *Part 1:* The author has been a consultant for companies that make antidepressants, including Eli Lilly, SK Life Sciences, Lundbeck, Takeda, Bristol-Myers Squibb, and GlaxoSmithKline, and has received operating grants from some of these companies. It is likely that he will in the future receive consulting contracts or operating grants from companies that make MAO-A inhibitors. He has applied for a patent to use MAO-A measures to predict the course of illness and to treat major depressive disorder. , *Part 2:* The author has been a consultant for companies that make antidepressants, including Eli Lilly, SK Life Sciences, Lundbeck, Takeda, Bristol-Myers Squibb, and GlaxoSmithKline, and has received operating grants from some of these companies., *Part 4:* The author has been a consultant for companies that make antidepressants, including Eli Lilly, SK Life Sciences, Lundbeck, Takeda, Bristol-Myers Squibb, and GlaxoSmithKline, and has received operating grants from some of these

companies.

**David Michelson:** *Part 1:* Employee of Merck and Co., *Part 2:* Merck salary and stock, *Part 3:* Merck employee

**Emmanuel Mignot:** *Part 1:* Novo Nordisk - consulting Jazz Pharmaceuticals - consulting GSK - Advisory Board

**Jennifer Mitchell:** *Part 1:* I am a founding member of a company that will eventually provide ex vivo GPCR screening.

**Lisa Monteggia:** *Part 1:* Speaker for Roche and Sepracor

**Elaine Morrato:** *Part 1:* I have received research grant funding through my university from Janssen Pharmaceuticals, Inc., *Part 4:* I have received research grant funding through my university from Janssen Pharmaceuticals, Inc (2012).

**John Morrison:** *Part 2:* I have developed monoclonal antibodies that are sold as research reagents that generate royalties in excess of \$10,000 per year.

**Charles Nemeroff:** *Part 1:* Research/Grants: National Institutes of Health (NIH), Agency for Healthcare Research and Quality (AHRQ) Speakers Bureau: None Consulting: Xhale, Takeda, SK Pharma, Shire, Roche, Lilly Stockholder: CeNeRx BioPharma, PharmaNeuroBoost, Revaax Pharma, Xhale, NovaDel Pharma Other Financial Interests: CeNeRx BioPharma, PharmaNeuroBoost Patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1) Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2) Scientific Advisory Boards: American Foundation for Suicide Prevention (AFSP), CeNeRx BioPharma, National Alliance for Research on Schizophrenia and Depression (NARSAD), Xhale, PharmaNeuroBoost, Anxiety Disorders Association of America (ADAA), Skyland Trail, AstraZeneca Pharmaceuticals (2009) Board of Directors: AFSP, Mt. Cook Pharma (2010), NovaDel (2011), Skyland Trail, Gratitude America Income sources or equity of \$10,000 or more: AstraZeneca Pharmaceuticals (2009), PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax Pharma, American Psychiatric Publishing, Xhale , *Part 2:* Income sources or equity of \$10,000 or more: AstraZeneca Pharmaceuticals (2009), PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax Pharma, American Psychiatric Publishing, Xhale

**Eric Nestler:** *Part 1:* PsychoGenics, SAB chair Merck, Consultant Berg Pharma, Consultant , *Part 2:* PsychoGenics, SAB chair Merck, Consultant Berg Pharma, Consultant

**John Newcomer:** *Part 1:* AstraZeneca Pharmaceuticals Bristol-Myers Squibb BioVail H. Lundbeck Obecure Otsuka Pharmaceuticals Sepracor, Inc. Solvay Pharma, Inc. Teva Pharmaceutical Dainippon Sumitomo Pharma America, Inc. Organon Pharmaceuticals USA Inc. Schering-Plough / Merck Vivus, Inc. Consultant to Litigation Boehringer-Ingelheim, *Part 3:* AstraZeneca Pharmaceuticals Bristol-Myers Squibb BioVail H. Lundbeck Obecure Otsuka Pharmaceuticals Sepracor, Inc. Solvay Pharma, Inc. Teva Pharmaceutical Dainippon Sumitomo Pharma America, Inc. Organon Pharmaceuticals USA Inc. Schering-Plough / Merck Vivus, Inc. Consultant to Litigation Boehringer-Ingelheim, *Part 4:* The National Institute of Mental Health (NIMH) Bristol-Myers Squibb Pfizer, Inc.

**Ginger Nicol:** *Part 1:* Dr. Nicol has received research funding from the National Institute of Mental Health (NIMH), NARSAD, the Dana Brown Charitable Trust Foundation, the Sidney R. Baer, Jr. Foundation, and the CHADS Coalition for Mental Health. She also receives grant support from Pfizer, Inc. for an investigator-initiated clinical trial. She receives royalties from Jones & Barlett Learning for development of a pediatric metabolic monitoring form and has consulted to MedScope. She does not participate in speakers' bureaus., *Part 4:* Investigator initiated clinical trial grant support: Pfizer, Inc.

**Michael Nitsche:** *Part 1:* Advisory Boards: UCB, Eisai, GSK, Starstim

**Charles O'Brien:** *Part 1:* Alkermes consultant Reckitt consultant Embera consultant , *Part 2:* Alkermes Consultant

**Charles O'Brien:** *Part 1:* Alkermes-Consultant Embera- Consultant Reckitt-Consultant, *Part 2:* Alkermes- Consultant over 2 years

**M. Foster Olive:** *Part 1:* April - November 2011 - Principal Investigator of contract work for Gilead Sciences

**Alvaro Pascual-Leone:** *Part 1:* Neosync “ Member of Scientific Advisory Board Starlab “ Member of Scientific Board Neuronix “ Member of Medical and Scientific Advisory Board Johnson & Johnson, Codman “ Member of Medical Advisory Board on Neurological and Neurosurgical Technology Nexstim “ Advisory Board Member Novavision “ Chair, Advisory Board Member Institut Guttman, Spain - Member, Board of Scientific Advisors. , *Part 4:* Investigator initiated grants from Neuronix, Nexstim, Neuronetics

**Mani Pavuluri:** *Part 2:* AstraZeneca speaker, *Part 4:* Abbott Laboratories and Janssen Pharmaceuticals supplied placebo and active drug for NIH Funded Divalproex vs. Risperdal Double-Blind Placebo Controlled Trial.

**Katharine Phillips:** *Part 1:* Forest Laboratories (medication only for an NIMH-funded study) Transcept Pharmaceuticals (research funding) Oxford University Press (royalties) Guilford Publications and The Free Press (potential royalties) Elsevier (future honorarium), *Part 2:* NIMH, FDA, Rhode Island Hospital, Alpert Medical School of Brown University, *Part 4:* Forest Laboratories (medication only for an NIMH-funded study) Transcept Pharmaceuticals (research funding)

**Daniel Pine:** *Part 2:* Clinical Practice; Editor, American Journal of Psychiatry; NIMH Researcher

**William Potter:** *Part 1:* Consultant to: AgeneBio, Amgen, Astellas, BMS, EnVivo, Envoy, Index Ventures, J&J, MedAvante, Orasi, Otsuka, Pfizer, Sonkei, Takeda, Theravance, *Part 2:* Merck and Eli LillyStock, *Part 3:*Merck in 2010

**Joseph Price:** *Part 2:* Faculty salary from Washington University in St. Louis

**Eugenii Rabiner:** *Part 1:* Until October 2011, was a full time employee of GlaxoSmithKline. I am currently a consultant for GlaxoSmithKline, Biotie and Takeda., *Part 2:* Full time employee of GlaxoSmithKline up to October 2011

**Scott Rauch:** *Part 1:* UTSW Grand Rounds - Honorarium (2010) Cleveland Clinic Grand Rounds - Honorarium (2010) NIMH Conte Center - OCD Advisory Board - Honorarium (2010) NIMH RDoC - Honorarium (2011) Hall Mercer - Board Member (2010 & 2011) Oxford University Press - Royalty (2010 & 2011) APPI - Royalty (2010 & 2011) , *Part 2:* None other than primary employer: McLean Hospital/Partners Healthcare.,*Part 3:* None other than primary employer: McLean Hospital/Partners Healthcare., *Part 4:* Cyberonics Medtronic

**Darrel Regier:** *Part 4:* Dr. Darrel A. Regier, Director of APIRE and Director of the Division of Research, American Psychiatric Association, oversees all Federal and industry sponsored research and research training grants in APIRE but receives no external salary funding or honoraria from any government or industry sources.

**Perry Renshaw:** *Part 1:* I am a Consultant and stockholder for Ridge Diagnostics, I am a Consultant for Kyowa Hakko Kirin. I have received royalties on a patent describing the use of uridine to treat bipolar depression from Repligen.

**Susan Resnick:** *Part 1:* Spouse: Research funding from Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis; Spouse: Consultant Amgen , *Part 4:* Spouse: Research funding Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis

**Robert Ring:** *Part 1:* I was a full time employee of Pfizer Worldwide Research and Development until May 2011 before joining the non-profit foundation Autism Speaks in my current role., *Part 2:* I was a full time employee of Pfizer Worldwide Research and Development until May 2011 before joining the non-profit foundation Autism Speaks in my current role., *Part 3:* I was a full time employee of Pfizer Worldwide Research and Development until May 2011 before joining the non-profit foundation Autism Speaks in my current role.

**Trevor Robbins:** *Part 1:* Consultancy: regular: Cambridge Cognition; E. Lilly inc, Lundbeck, GlaxoSmithKline, Merck, Pfizer, ChemPartners Shanghai, Shire Pharmaceuticals. Royalties for CANTAB (Cambridge Cognition), Editing the journal 'Psychopharmacology' (Springer-Verlag), *Part 2:* Cambridge Cognition, Pfizer (2010 only), *Part 3:* Cambridge Cognition, *Part 4:* E. Lilly, Lundbeck, GlaxoSmithKline

**Timothy Roberts:** *Part 1:* Research Support received from Seaside Therapeutics Consulting, Prism Clinical Imaging, *Part 4:* Research Support received from Seaside Therapeutics

**Bruce Rosen:** *Part 1:* Siemens, ABIA (Amyloid Related Imaging Abnormalities, Janssen Scientific, Wolf Greenfield, *Part 2:* Wolf Greenfield

**Thomas Roth:** *Part 1:* Grants: Apnex, Aventis, Cephalon, GlaxoSmithKline, Merck, Neurocrine, Pfizer, Sanofi, SchoeringPlough, Sepracor, Somaxon, Somnus, Syrex, Takeda, Trancept, Ventus, Wyeth, Xenoport, Consultants: Abbott, Accadia, Acogolix, Acorda, Actelion, Addrenex, Alchemers, Alza, Ancel, Arena, AstraZenca, Aventis, AVER, Bayer, BMS, BTG, Cephalon, Cypress, Dove, Eisai, Elan, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Hypnion, Impax, Intec, Intra-Cellular Jazz, Johnson and Johnson, King, Lundbeck, McNeil, MediciNova, Merck, Neurim, Neurocrine, Neurogen, Novadel, Novartis, Ocera, Orexo, Organon, Otsuka, Prestwick, Proctor and Gamble, Pfizer, Purdue, Resteva, Roche, Sanofi, Schoering Plough, Servier, Shire, Somaxon, Somnus, Steady Sleep Rx, Syrex, Takeda, Transcept, Vanda, Ventus, Vivometrics, Wyeth, Yamanuchi, Xenoport, Speakers: Sepracor, Somaxon, *Part 4:* Pfizer, Merck

**David Rubinow:** *Part 1:* Ad hoc consultant, Pfizer Pharmaceuticals, *Part 2:* Editorial Board, Dialogues in Clinical Neuroscience

**Barbara Sahakian:** *Part 1:* Professor Barbara Sahakian consults for Cambridge Cognition. She has consulted for Novartis, Shire, GlaxoSmithKline, Lilly, Boehringer-Ingelheim and Hoffmann-La Roche. She holds a grant funded by Johnson and Johnson. She was on the Medical Research Council Neurosciences and Mental Health Board (2010) and on the Science Co-ordination Team for the Foresight Project on Mental Capital and Wellbeing, 2008 (Office of Science, The



Department of Innovation, Universities and Skills,). She was on Panel LS5 for the European Research Council. As an Associate Editor, she also receives an honorarium from the journal Psychological Medicine. Prof. Robbins has consulted for Cambridge Cognition, Lundbeck, Pfizer, and Lilly, and has received research grants from GlaxoSmithKline, Lundbeck and Lilly., *Part 4*: Professor Sahakian holds a grant funded by Johnson and Johnson.

**Gerard Sanacora:** *Part 1*: Dr. Sanacora has received consulting fees from Abbott Laboratories, AstraZeneca, Avanier Pharmaceuticals, Bristol-Myers Squibb, Evotec, Eli Lilly & Co., Hoffman La-Roche, Novartis, and Novum Pharmaceuticals. In addition Dr. Sanacora is a co-inventor on filed patent application by Yale University (PCTWO06108055A1)., *Part 2*: Eli-Lilly & Co., *Part 4*: Dr. has received additional grant support from AstraZeneca, Bristol-Myers Squibb, Hoffman La-Roche, Merck & Co., and Sunovion.

**Alena Savonenko:** *Part 1*: Jonson&Jonson, *Part 4*: Jonson&Jonson, MAPP

**Akira Sawa:** *Part 1*: Research Support: Astellas Pharm., Dainippon Sumitomo, Mitsubishi - Tanabe Pharm., Takeda Consultant: Pfizer, Asubio, Sucampo, Eli Lilly, Taisho Collaboration: Pfizer, Afraxis, Astellas Pharm., Dainippon Sumitomo, Mitsubishi - Tanabe Pharm., Takeda, Sanofis-Avenis

**Eric Schadt:** *Part 1*: SAB of Pacific Bio Sciences, Berg Pharma, and NuMedii

**Alan Schatzberg:** *Part 1*: Corcept, PharmaNeuroBoost, Forest, Merck, Neurocrine, Jazz, Xhale, Delport, Biotie, Envivo, CeNeRx, BrainCells, Sunovion, Eli Lilly, Sanofi-Aventis, Takeda, Neuronetics, Cervel, Velocity, *Part 2*: Corcept, PharmaNeuroBoost, Pfizer, Forest, Merck, Neurocrine, Amnestix, *Part 3*: PharmaNeuroBoost

**Christopher Schmidt:** *Part 1*: I am employed by Pfizer, Inc, *Part 2*: Pfizer, Inc, *Part 3*: Pfizer, Inc

**Mark Smith:** *Part 1*: I am an AstraZeneca employee

**Linda Spear:** *Part 2*: SUNY Research Foundation; State of New York; TIAA/CREF; Ameriprise Financial; HSBC Bank; SEFCU

**Reisa Sperling:** *Part 1*: Consulting for Bayer, Biogen-IDEC, Bristol-Myers-Squibb, Eisai, Eli Lilly, Janssen, Pfizer, Roche, *Part 4*: Pfizer, Janssen, Bristol-Myers-Squibb, Medivation

**Stephen Stahl:** *Part 1*: Advent, Alkermes, Arbor Scientia, Arena, Astra Zeneca, Avanir, Biomarin, Boehringer, Ingelheim, Bristol Myers Squibb, Cenerex, Cypress Bioscience, Dey, Eli

Lilly, Forest, GenOmind, J & J, Janssen, Jazz, LaboPharm, Lundbeck, Merck, Neuronetics, Neuroscience Education Institute, Novartis, Noven, ONO, Orexigen, Otsuka, PamLabs, Pfizer, PgxHealth, RCT Logic, Rexahn, Roche, Royalty Pharma, Schering Plough, Sepracor, Servier, Shire, Solvay, Sunovion, Trius, Valeant, Vivus , *Part 2*: Arbor Scientia, Astra Zeneca, Biomarin, Boehringer Ingelheim, Dey, Eli Lilly, Forest, GenOmind, GlaxoSmith Kline, Merck, Neuronetics, Neuroscience Education Institute, Novartis, Orexigen, Otsuka, PamLabs, Pfizer, PGxHealth, Roche, Servier, Sunovion , *Part 4*: Astra Zeneca, Avanir, BioMarin, Cenerex, Dainippon Sumitomo, Dey, Eli Lilly, Forest, GenOmind, Lundbeck, Merck, Neuronetics, Novartis, Otsuka, PamLab, Pfizer, PGX Health, Roche, Schering Plough, Sepracor, Servier, Shire, Sunovion, Torrent, Trovis, Valeant

**Thomas Steckler:** *Part 1*: Employee of Janssen Research & Development, a division of Janssen Pharmaceutica NV

**Murray Stein:** *Part 1*: UpToDate: Co-Editor-in-Chief for Psychiatry Content Depression and Anxiety (journal): Deputy Editor, *Part 2*: University of California San Diego VA San Diego Healthcare System UpToDate Depression and Anxiety (journal): Wiley Press

**Camilla Stoltenberg:** *Part 2*: Norwegian institute of public health (government funded) and University of Bergen (public university, government funded)

**Edith Sullivan:** *Part 2*: Editor-in-chief, Neuropsychology Review

**James Swanson:** *Part 1*: Noven and Trancept

**Neal Swerdlow:** *Part 1*: Summer 2011: 1 day of consulting for Neurocrine, Inc.

**Joseph Takahashi:** *Part 1*: Co-founder and SAB member of Reset Therapeutics, Inc., *Part 2*: Co-founder and SAB member of Reset Therapeutics, Inc.

**Michael Thase:** *Part 1*: Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly & Co, Dey Pharma LP, Forest Laboratories, H. Lundbeck A/S, MedAvante Inc, Merck & Co Inc, Neuronetics Inc, Otsuka, Ortho-McNeil Pharmaceuticals, PamLab LLC, Pfizer, PGx Inc, PharmaNeuroboost, Rexahn, Roche Labs, Shire US Inc, Takeda, Transcept Pharmaceuticals , *Part 2*: University of Pennsylvania, *Part 4*: Alkermes, Eli Lilly and Company, Forest Pharmaceuticals, Otsuka Pharmaceuticals, PharmaNeuroboost, Roche Labs

**Kay Tye:** *Part 1*: Stanford University has filed for patent protection on a technology invented by myself and Karl Deisseroth. I do not receive research funding, royalties or consultant fees from any company., *Part 2*: Salary from Stanford University and stipend from my post-doctoral

NRSA Currently, get salary from MIT, Picower Institute and Brain and Cognitive Sciences Department

**Sophia Vinogradov:** *Part 1:* Brain Plasticity INstitute, Inc.-- consultant on two NIMH SBIR grants. Genentech-- consultant. Amgen-- consultant. Hoffman-LaRoche-- consultant.

**Dean Wong:** *Part 2:* Dr. Wong is employed by the Johns Hopkins University, School of Medicine His wife, Dr. Susan Resnick, is employed by NIA/NIH., *Part 4:* In addition to research funding from NIH, Dr. Wong has received funding from: Amgen, Avid, Biotie, GE, Intracellular, Johnson and Johnson, Lilly, Lundbeck, Merck, Otsuka, Roche, Sanofi-Aventis.

**Marcelo Wood:** *Part 4:* My lab received a Sponsored Research Agreement from Repligen Corp., which supported research and Repligen provided small molecule inhibitors for our research.

**Allan Young:** *Part 1:* Professional involvement with all leading companies in the field of mood disorders in the last 2 years including: AstraZeneca, Janssen, GSK, Otsuka, BMS, Eli Lilly, Servier, Sanofi, and Brain Cells Inc.

**Carlos Zarate:** *Part 1:* Dr. Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Dr. Zarate has assigned his rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government.

**Han-Ting Zhang:** *Part 1:* Asubio Pharmaceuticals Cordex Biosolutions Lundbeck Pharmaceuticals, *Part 4:* Lundbeck Pharmaceuticals

Following Faculty Had No Disclosures:

Huda Akil  
Cristina Alberini  
Gary Aston-Jones  
Tracy Bale  
Mark Bear  
Carrie Bearden  
Jill Becker  
Grant T. Belgard  
Catherine Belzung  
Francine Benes  
Jennifer Blackford  
Antonello Bonci  
Linda Brady  
Kristen Brennand  
Alan Brown  
William Bunney  
Katherine Burdick  
Judy Cameron  
Michael Caplan  
Adam Carter  
Francisco Xavier Castellanos  
BiGS Consortium  
Anis Contractor  
Sam Cooke  
William Copeland  
Richard Davidson  
Luis de Lecea  
Etienne de Villers-Sidani  
Nancy Diazgranados  
Theodora Duka  
Yogesh Dwivedi  
Howard Eichenbaum  
Monique Ernst  
Kate Fitzgerald  
Elizabeth Flandreau  
Andrew Fox  
Sophia Frangou  
Guido Frank  
Thomas Franke

Bob Freedman  
Felipe Fregni  
Rita Fuchs  
Wenbiao Gan  
Hugh Garavan  
John Gilmore  
David Glahn  
Susan Goebel-Goody  
Howard Goldman  
Jill Goldstein  
Rita Goldstein  
Charles Grob  
Lisa Gunaydin  
Raquel Gur  
Frank Haist  
Ming-Hu Han  
Robert Handa  
Shawn Harmon  
Mary Heitzeg  
Derik Hermann  
Matt Hill  
Jussi Hirvonen  
Tomas Hokfelt  
Elaine Hsiao  
Yasmin Hurd  
Kent Hutchison  
Thomas Insel  
Marcus Ising  
Sari Izenwasser  
Carrie Jones  
Atsushi Kamiya  
John Katzenellenbogen  
Walter Kaye  
Joel Kleinman  
Ami Klin  
Cynthia Kuhn  
Amanda Law  
Ellen Leibenluft  
Jeff Lichtman  
Daniel Lightfoot  
Raye Litten  
Monica Luciana  
Beatriz Luna  
Ken Mackie  
Rachel Marsh  
Kimberley McAllister

Robert McCullumsmith  
Bruce Mcewen  
Jacqueline McGinty  
Kathleen Merikangas  
Paul Mermelstein  
Michael Milham  
Guo-li Ming  
Christopher Monk  
Marisela Morales  
Janice Naegele  
Alexander Neumeister  
Jack Nitschke  
Matthew Nock  
Patricio O'Donnell  
Neelroop Parikshak  
Paul Patterson  
Surojit Paul  
Martin Paulus  
Godfrey Pearlson  
Adolf Pfefferbaum  
Mary Phillips  
Daniele Piomelli  
Vijay Ramchandani  
Avi Reichenberg  
Kathryn Reissner  
Emilie Rissman  
Dorit Ron  
Amy Roy  
Scott Russo  
Anne Schaefer  
Michael Schoenbaum  
Thomas Schulze  
Barry Setlow  
Michael Silver  
Alan Simmons  
Manpreet Singh  
Rajita Sinha  
Dana Small  
Jordan Smoller  
Monsheel Sodhi  
Wolfgang Sommer  
Dietmar Spengler  
Elliot Stein  
Garret Stuber  
David Sweatt  
Susan Swedo

Michael Taffe  
Nim Tottenham  
Daniela Tropea  
Kuei Tseng  
Tim Tully  
Robert Ursano  
Pierre Vincent  
Nora Volkow  
James Waltz  
Daniel Weinberger  
Danny Winder  
Catherine Woolley  
Anthony Wynshaw-Boris  
Deborah Yurgelun-Todd  
Natalie Zahr